Polish Journal of Pathology
eISSN: 2084-9869
ISSN: 1233-9687
Polish Journal of Pathology
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

without publication fees
3/2025
vol. 76
 
Share:
Send email
Share:
abstract:
Original paper

Impact of age and histological type on programmed death-ligand 1 expression in non-small cell lung cancer – a single-center analysis of 1,606 cases

Anna Szumera-Ciećkiewicz
1
,
Piotr Wiśniewski
2
,
Agnieszka Tomczyk-Szatkowska
3
,
Magdalena Rosińska
4
,
Dorota Pierzchała
1
,
Joanna Owczarek
2
,
Kinga Winiarczyk
5
,
Patrycja Wołoszyn
1
,
Maciej Krzakowski
5
,
Magdalena Knetki-Wróblewska
5

  1. Biobank, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland
  2. Department of Pathology, Military Medical Institute, Warsaw, Poland
  3. Department of Pathology, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland
  4. Digital Medicine Center, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland
  5. Department of Lung Cancer and Chest Tumors, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland
Pol J Pathol 2025; 76 (3): 177-186
DOI: https://doi.org/10.5114/pjp.2025.157974
Online publish date: 2025/12/30
View full text Get citation
 
PlumX metrics:
Programmed death-ligand 1 (PD-L1) guides immune checkpoint inhibitor use in non-small cell lung cancer (NSCLC), yet its variation by age and histology remains uncertain. We retrospectively evaluated 1,606 consecutive NSCLC cases (2017–2022) with PD-L1 immunohistochemistry (IHC) on formalin-fixed, paraffin- embedded samples. Patients were grouped by age (< 60, 60–79, ≥ 80 years) and tumor proportion score (TPS), categorized as < 1%, 1–49%, or ≥ 50%. Associations were tested using the ² test, and independent predictors were identified using multinomial logistic regression.

High PD-L1 expression (TPS ≥ 50%) occurred in 33.6% of patients, intermediate (1–49%) in 23.6%, and negative (< 1%) in 42.7%. Programmed death-ligand 1 expression ≥ 1% was most frequent in squamous cell carcinoma (63.0%), followed by adenocarcinoma (55.0%), and was least common in large cell carcinoma (36.0%; p = 0.002). Overall proportions of PD-L1 ≥ 1% did not differ significantly by age. However, patients aged ≥ 80 had nearly twice the likelihood of high expression compared to those < 60 (relative risk ratio, 1.92; 95% CI: 1.11–3.34; p = 0.02), independent of the histotype.

Programmed death-ligand 1 expression in NSCLC shows distinct histotype-related patterns and a modest, age-related trend toward higher values in the oldest group. These data support routine PD-L1 assessment and suggest that advanced age alone should not preclude consideration of immunotherapy. Findings may inform trial design and real-world treatment decision-making.
keywords:

PD-L1, non-small cell lung cancer, expression, age, histological type
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2025 Termedia Sp. z o.o.
Developed by Bentus.